Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARAPAN II: TB Prevention in Malaysian Prisons
NCT03089983Completed
- Sponsor
- Yale University
- Start
- Aug 2017
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifapentine in Tuberculosis (TB) (2 arms), sponsored by Yale University. Primary endpoint: TB Treatment Completion Rates in Prison. Started Aug 2017; status: completed.
02
Drugs
rifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03089983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089983.